Chen Liang Ph.D

Senior Scientist II Novo Nordisk

Chen Liang obtained a Ph.D. In biophysics chemistry at Emory University in 2017. She worked for peptide-based drug delivery at NIH from 2018-2020. Her working experience spans from big pharma to biotech and has experience in both protein and oligo delivery.

Seminars

Tuesday 28th April 2026
Leveraging Peptide Drug Conjugates to Unlock New Targets & Expand Therapeutic Options in Oncology & Beyond
10:00 am

Peptide-Drug Conjugates (PDCs) are rising as a key next-generation therapeutic avenue, combining the precise targeting of peptides with the potency of cytotoxic drugs to treat cancers and other diseases. Several challenges to this technology however include their clinical potential due to stability, ligand binding specificity and target affinity which remains a significant challenge. This workshop will provide insights into the future direction of PDCs as a promising application to unlock new targets and expand therapeutic applications.

Chen Liang Ph.D